Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 9, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-016-0290-1
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81101726]
- CAHON Young Investigator Award
Ask authors/readers for more resources
T790M mutation is the most common mechanism for resistance to first-and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. Resistance to AZD9291 has been described. C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors. This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available